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Abstract
Background: The A-allele of the single nucleotide polymorphism (SNP), rs9939609, in the FTO gene is associated with
increased fatness. We hypothesized that the SNP is associated with morbidity and mortality through the effect on fatness.
Methodology/Principal Findings: In a population of 362,200 Danish young men, examined for military service between
1943 and 1977, all obese (BMI$31.0 kg/m
2) and a random 1% sample of the others were identified. In 1992–94, at an
average age of 46 years, 752 of the obese and 876 of the others were re-examined, including measurements of weight, fat
mass, height, and waist circumference, and DNA sampling. Hospitalization and death occurring during the following median
13.5 years were ascertained by linkage to national registers. Cox regression analyses were performed using a dominant
effect model (TT vs. TA or AA). In total 205 men died. Mortality was 42% lower (p=0.001) with the TT genotype than in A-
allele carriers. This phenomenon was observed in both the obese and the randomly sampled cohort when analysed
separately. Adjustment for fatness covariates attenuated the association only slightly. Exploratory analyses of cause-specific
mortality and morbidity prior to death suggested a general protective effect of the TT genotype, whereas there were only
weak associations with disease incidence, except for diseases of the nervous system.
Conclusion: Independent of fatness, the A-allele of the FTO SNP appears to increase mortality of a magnitude similar to
smoking, but without a particular underlying disease pattern barring an increase in the risk of diseases of the nervous
system.
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Introduction
Various studies have shown that a series of common single
nucleotide polymorphisms (SNPs) in the first intron of the FTO
gene is associated with higher body-mass index (BMI) and risk of
obesity in European cohorts [1–4]. These SNP’s are in tight linkage
disequilibrium so studies of only one of them will convey the effect.
Since fatness, and especially abdominal fatness, is associated with
increased mortality [5–7], we hypothesized that the FTO SNP,
rs9939609, T/A with a minor A-allele frequency in Caucasians of
0.45, is associated with mortality through its association with
fatness-related diseases (GenBank accession no.: NT_010498). We
therefore investigated the association between this SNP and
morbidity and mortality with and without adjustment for fatness.
Methods
Study population
Among 362,200 Caucasian men examined at the mean age of
20 years at the draft boards in Copenhagen and its surroundings
during 1943–77, a randomly selected group of one in every
hundred men (n=3,601) and all obese men (n=1,930) were
manually identified (referred to as survey S-20) [8;9]. Obesity was
defined as 35% overweight relative to a local standard in use at the
time, corresponding to a BMI$31.0 kg/m
2, which proved to be
above the 99
th percentile. All obese and half of the random
sample, still living in the region, were invited to a follow-up survey
in 1992–94. Due to the long sampling period (1943–1977) the age
range at follow-up was wide, resulting in a mean age of 46 years
(referred to as survey S-46) [4;10]. The participation rate was
50.5% among the obese and 64.4% among the randomly sampled,
equivalent to 795 obese and 920 randomly sampled men attending
the examination (figure 1), which included sampling of blood, from
which DNA was extracted. Genotyping of FTO rs9939609
(Taqman allelic discrimination; KBiosciences, Cambridge, UK)
was successful in 96% of the samples - 752 obese and 876
randomly sampled men - with an error rate of 0.72% calculated
from 553 duplicate samples in men that additionally had blood
drawn at a mean age of 49 years (referred to as S-49). In case of
genotype discrepancy, the genotype from S-49 was used, since the
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Population stratification may occur due to differences in allele
frequencies between the obese and randomly sampled men owing
to systematic differences in ancestry rather than association of
genes with the response variable. However, our cohort study
design of Danish Caucasian men where the randomly sampled
men come from the same population in which the obese men were
identified effectively prevents population stratification. This is
reflected in the genotype distributions of the sample, which obeyed
Hardy-Weinberg equilibrium (p=0.27). The attrition of the
groups over time implied that the segment of subjects that were
followed up and genotyped represent a population of approxi-
mately 175,000 men (represented by the 0.5% random sample of
876 men (200*876=175.200)) and the originally obese men in this
population. The median BMI at time of draft board examination
was 21.3 (range: 15.7–30.9) among randomly sampled men
included in the present study compared to a median BMI of
21.4 (range: 15.7–30.9) for randomly sampled men excluded from
this study (for any reason). Similarly, for obese men included in the
present study the median BMI at draft board examination was
32.5 (range: 31.0–51.8) versus 32.8 (range: 31.0–45.9) among
obese men not included in the present study (for any reason).
Objective measures of weight and height were obtained at S-20
and S-46, and additionally, waist circumference was measured at
S-46. BMI was calculated as weight in kilograms divided by the
square of height in meters. Total body fat mass was assessed by
bioimpedance at S-46, and fat body-mass index (fat-BMI) was
calculated as weight of body fat mass in kilograms divided by the
square of height in meters. Bioimpedance has proved to be
reasonable accurate for assessing body composition (fat mass and
fat free mass) in cohort studies [11].
The Danish Civil Registration System was established on April
2, 1968 [12]. All Danish residents alive or born thereafter have
been assigned a unique identification number, referred to as their
CPR number. Information on vital status and occurrence of
disease was obtained by linking the subjects’ CPR number to the
Civil Registration System and the National Hospital Discharge
Register [13], respectively, until October 31, 2007. Information on
causes of death was obtained by linkage to the National Cause of
Death Register [14] until 2007. Using an explorative approach,
the sequences of diseases that had contributed to death according
to the death certificate were investigated. In case of co-morbidity,
a subject was only allowed to appear in each disease category once,
but in several disease categories simultaneously. An additional
approach was undertaken to investigate the occurrence of disease
in the year preceding death in men who died during follow-up.
Diseases occurring in this year convey supplementary information
on diseases that may have contributed to death. The incidence of
Figure 1. Participation flow chart from draft board examination.
doi:10.1371/journal.pone.0004428.g001
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first hospitalization following the survey as recorded in the
National Hospital Discharge Register. The causes of death and
hospital discharge diagnoses were classified according to the
International Classification of Diseases, Eighth Revision (ICD-8)
before 1994 and the Tenth Revision (ICD-10) thereafter. The
coverage of each register is high, with virtually every event
recorded [13;14].
Ethics statement
The Danish Data Protection Agency and the Ethical Commit-
tees of Copenhagen and Frederiksberg municipalities approved
the study, which was in accordance with the Helsinki Declaration
II. All participants signed written consent before participating.
Statistical analyses
Our study sample represents the entire BMI distribution
through the random sample and with the right end of the
distribution being richly represented. Therefore, the data actually
consists of a cohort with two nested sub-cohorts based on the
different sampling fraction across the range of BMI at draft board
examination. This design implies that the data can be analysed as
combined cohort data [15]. Cox proportional-hazards regression
was used to test our a priori hypothesis of an association between
FTO genotype and all-cause mortality. Analyses were performed
for the original obese and the randomly sampled cohorts
separately and combined, with and without adjustment for the
various fatness covariates. No statistical interactions between
genotype and the original sampling groups with regard to
associations to the outcomes were observed. We explored the
pattern of cause-specific mortality and morbidity. The analyses
were performed for the two sampling cohorts combined with
adjustment for BMI S-20 and BMI S-46.
For each Cox proportional-hazards model the subjects were
followed from date of entry into S-46 until date of death, censoring
due to loss to follow-up, emigration, or end of follow-up at
October 31, 2007, in the Civil Registration System. The largest
group (the carriers of the A-allele) was used as reference, in order
to obtain the most precise estimates. The underlying time-scale
was age, with delayed entry from age at S-46, which maximizes
comparability by age [16]. Results are presented as hazard ratios
(HR) with 95% confidence intervals (CI), and p-values ,0.05 were
considered significant. Linearity of the covariates was tested
against a restricted cubic spline with five knots [17], and if the
assumption of linearity was not fulfilled the covariates were
included as restricted cubic splines. For every Cox model, the
proportional hazards assumption was controlled with a smoothed
plot of scaled Schoenfeld residuals versus time. Likelihood ratio
tests were used to estimate whether a model including both fatness-
covariates and the FTO SNP enhanced model fit compared to a
model including only fatness-covariates. All analyses were
performed in STATA version 9.2 (Stata Corporation, Texas;
www.stata.com).
Results
Out of the total of 1,628 men included in the analyses, 205 men
died during the median 13.5 years of follow-up. The genotype
distribution differed as expected between the originally obese men
(TT, 25.5%, TA, 47.6%; AA, 26.9%) and the randomly sampled
men (TT, 32.7%; TA, 50.6%, AA, 16.8%), corresponding to a
minor allele frequency of 0.51 in the obese group, 0.42 in the
random sampled group and 0.46 combined. The obese were
slightly younger than the other men due to the increasing
prevalence of obesity during the recruitment period (Table 1).
The odds ratio for having a BMI$31.0 at time of draft board
examination was 2.05 (95% CI, 1.55–2.71; p,5*10
27) for the AA
genotype versus the TT genotype.
All-cause mortality
The mortality in the obese group was, as expected, greater than
in the randomly selected group, with a HR of 2.03 (95% CI, 1.50–
Table 1. Distribution of age and anthropometrics given as median and range of 1,628 Danish men according to genotype for FTO
rs9939609
TT TA AA
N=478 N=801 N=349
No of subjects Obese 192 358 202
Random sample 286 443 147
No of deaths Obese 14 54 30
Random sample 26 63 18
Age (yr) S-46 Obese 41 (34–66) 43 (33–73) 41 (33–75)
Random sample 46 (34–71) 47 (34–73) 46 (34–67)
BMI (kg/m
2) S-20 Obese 32.5 (31.0–42.8) 32.5 (31.0–45.4) 32.7 (31.0–51.8)
Random sample 21.3 (15.9–29.4) 21.2 (15.7–30.9) 21.4 (16.3–29.7)
BMI (kg/m
2) S-46 Obese 34.6 (24.3–63.7) 34.9 (19.9–51.5) 35.6 (25.2–59.6)
Random sample 25.7 (18.0–36.5) 25.8 (16.2–45.1) 25.9 (19.4–41.9)
Waist (cm) S-46 Obese 115.5 (79.5–183.0) 116.8 (84.0–160.0) 117.0 (81.0–171.5)
Random sample 92.2 (70.0–130.0) 93.0 (66.0–131.0) 93.2 (58.0–139.0)
Fat-BMI (kg/m
2) S-46 Obese 11.8 (4.9–32.1) 12.0 (3.4–24.3) 12.4 (4.7–26.7)
Random sample 6.3 (1.2–13.3) 6.4 (0.3–19.2) 6.2 (1.5–16.6)
Abbreviations: BMI, body mass index; fat-BMI, fat mass (kg)/height
2 (m
2); N, number of subjects; S-20, draftee population of median age 20; S-46, follow-up survey at
median age 46
doi:10.1371/journal.pone.0004428.t001
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and AA genotypes) gave the best fit to the mortality data as
illustrated in Table 2. This was confirmed by likelihood ratio tests
(LRT) where an additive effect of the gene (LRT, 2.65; P=0.10), a
dominant effect of the gene (LRT, 0.45; P=0.50) and a recessive
effect of the gene (LRT, 10.77; P=0.001) were tested. A decreased
mortality in men with the TT genotype compared to A-allele
carriers was observed, both among obese and the randomly
sampled, and since there was no interaction, a pooled estimate was
made; HR, 0.58; 95% CI, 0.41–0.82 (Table 3). The association
was attenuated only slightly and remained significant after
adjustment for BMI at S-46, waist circumference and BMI at S-
46, weight history (i.e. BMI at S-20 and S-46), and fat-BMI at S-46
(Table 3).
Exploratory study of disease pattern
Fat-BMI apparently had the strongest effect on the association
between the genotypes and all-cause mortality (Table 3), but since
data on fat-BMI was missing for 103 subjects, the cause-specific
analyses were instead adjusted for BMI at S-20 and S-46. The
results were essentially the same when fat-BMI was included as a
covariate instead of BMI at S-20 and S-46. Table 4 shows the
disease groups explored (ICD codes are available on request).
Circulatory diseases and cancers accounted for the highest
numbers of prevalent diseases at death, irrespective of genotype.
For the majority of the disease categories, the estimates were lower
for the TT genotype than for the A-allele carriers, although the
estimates were not significantly different from 1.00 (Table 4).
Remarkably, no individuals with the TT genotype died from or
with diseases of the nervous system, whereas ten such cases were
observed in the A-allele carriers.
Regarding diseases occurring during the year preceding death,
the HR’s were lower for the TT genotype (vs. TA and AA
genotypes) in all categories, though not significantly different from
1.00 (Table 4).
The HRs for incidence of diseases during the follow-up after
genotyping were in general very close to 1.00, indicating no
difference in risk between the genotypes. However, a significantly
lower risk was observed for endocrine diseases in TT versus A-
allele carriers (HR, 0.73; 95% CI, 0.55–0.96) as well as for diseases
of the nervous system (HR, 0.57; 95% CI, 0.40–0.82).
Discussion
The present findings show a strong fatness-independent
association between the FTO SNP, rs9939609, and all-cause
mortality in middle-aged men of a magnitude similar to that of
smoking [18], with a significantly decreased risk of dying in the TT
genotype group compared with A-allele carriers. This was
observed both in the random sample of the 362,200 Danish
draftees and in the selected sub-sample of the most obese men in
this population. Our a priori hypothesis – that the A-allele of the
FTO SNP was associated with increased mortality and morbidity
primarily through an effect on fatness – was thus not confirmed, as
our results showed only a slight attenuation of the HR by adjusting
for the fatness-covariates.
We observed that men with the AA genotype had a 2.05
increased odds of obesity compared with the TT genotype, which
is higher than reported in previous studies [1;19;20]. This
difference in odds ratios is most likely due to differences between
the examined cohorts. Our cohort is characterized by a massive
enrichment of the right tail of the BMI distribution, making it
possible to demonstrate a stronger association compared to
already published studies examining the effects of FTO on
fatness. Men with the TT genotype had decreased mortality from
most causes assessed. Our results suggest that the FTO SNP may
affect particularly the nervous system, however, the number of
cases with disease of the nervous system was small and could not
alone account for the excess mortality observed among A-allele
carriers.
In addition to death certificates providing the presumed
sequence of diagnoses leading to death as well as other prevalent
diseases, we also examinined inpatient registry data on diseases
occurring close to time of death, thereby obtaining the best
Table 2. FTO rs9939609 genotype distribution and all-cause
mortality in 1,628 Danish men
TT TA AA
HR 95% CI HR HR 95% CI
Obese 0.52 0.29–0.94 1.00 1.06 0.68–1.66
Random sample 0.63 0.40–0.99 1.00 1.02 0.60–1.73
Combined 0.59 0.41–0.84 1.00 1.05 0.75–1.48
Cox proportional hazards analysis with age as the underlying time scale and
delayed entrance at age at time of blood sampling (S-46)
Abbreviations: HR, Hazard ratio; CI, Confidence interval
doi:10.1371/journal.pone.0004428.t002
Table 3. FTO rs9939609 (genotype TT vs. TA and AA) and all-cause mortality in 1,628 Danish men
Obese Random sample Pooled
N HR 95% CIs P value HR 95% CIs P value HR 95% CIs P value
Crude 1,628 0.51 0.29–0.90 0.02 0.62 0.40–0.97 0.04 0.58* 0.41–0.82 0.001
Adjusted for BMI S-46 1,626 0.52 0.29–0.91 0.02 0.61 0.39–0.95 0.03 0.58* 0.41–0.82 0.002
Adjusted for BMI and waist S-46 1,624 0.51 0.29–0.91 0.02 0.59 0.38–0.92 0.02 0.57* 0.40–0.81 0.002
Adjusted for BMI S-20 and S-46 1,626 0.53 0.30–0.94 0.03 0.61 0.39–0.96 0.03 0.59* 0.41–0.83 0.003
Adjusted for fat-BMI S-46 1,523 0.59 0.33–1.05 0.07 0.64 0.41–1.01 0.06 0.63* 0.44–0.90 0.01
Cox proportional hazards analysis with age as the underlying time scale and delayed entrance at age at time of blood sampling (S-46). There was no interaction
between the genotypes and the original sampling variable (Random sample vs. obese)
Abbreviations: BMI, body mass index; fat-BMI, fat mass (kg)/height
2 (m
2); N, number of subjects with complete covariate information; HR, Hazard ratio; CI, Confidence
interval; S-20, draftee population of median age 20; S-46, follow-up survey at median age 46
*p,0.05 for the likelihood ratio test (Likelihood ratio tests were used to estimate whether a model including both fatness-covariates and FTO rs9939609 fitted the data
better than a model including only fatness-covariates)
doi:10.1371/journal.pone.0004428.t003
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diseases at death, assessment of these diseases showed lower risk
estimates for almost all disease categories among individuals with
the TT genotype. When analyzing incidence of diseases emerging
earlier on (but still after genotyping), the TT genotype was less
protective, hence suggesting that the genotype affects the subject’s
general ability to cope with disease once present rather than
affecting susceptibility to developing disease. However, for diseases
of the nervous and endocrine systems, a decreased occurrence was
observed already at this stage.
The FTO gene is of ancient origin and conserved in vertebrates
and marine algae [21;22]. Bioinformatics analyses suggests that
FTO encodes a DNA demethylase, up-regulated by feeding and
down-regulated by fasting [23] and studies suggest that the SNP
influences cerebro-cortical insulin sensitivity [24] and lipolytic
activity in adipose tissue of healthy individuals [25]. Our findings
suggest that the FTO SNP may have much wider implications than
the effect on fatness and the effects derived hereof. The
observation of an increased mortality among A-allele carriers
over the broad range of disease categories may translate into the
hypothesis that the cellular effects of the SNP affects most organs,
and particularly their ability to maintain or regenerate proper
function when afflicted by various diseases. The positive
association between A-allele carriers and disease of the nervous
system also needs further investigation. It may be related to the
high expression of FTO in fetal and adult brain tissues [1;2;21;23].
Due to the limited numbers of cases and the multiple testing, we
emphasize that our findings are purely hypothesis generating. To
test these hypothesis further research is warranted, both at the
level of mapping disease patterns at a more detailed level than the
organ specific disease categories performed here, and through
further examination of the functional impact of the FTO SNP.
Since the SNP is intronic it may exert functional effects through
altered expression of FTO, or the observed effects may putatively
be mediated via another gene.
There are several strengths of this study, but also limitations. It
is based on a unique, well-defined large background study
population of white men with the obese and random sample
derived from the same quite homogenous population, hence
eliminating population stratification. The complete sampling of an
obese group facilitates valid estimation of the associations between
the FTO SNP, fatness and morbidity and mortality, and hence also
of fatness-independent associations. The inclusion of a randomly
selected group gave us the possibility to reproduce our estimates as
Table 4. FTO rs9939609 (genotype TT vs. TA and AA) and
cause-specific mortality and morbidity in 1,628 Danish men
adjusted for BMI S-20 and S-46
TT TA and AA
Infectious diseases No HR 95% CIs No HR
Prevalent at time of death 3 1.17 0.30–4.60 7 1.00
Incident one year prior to death 4 0.55 0.18–1.63 17 1.00
First incidence 37 0.95 0.65–1.39 107 1.00
Cancer
Prevalent at time of death 13 0.84 0.43–1.66 51 1.00{
Incident one year prior to death 14 0.68 0.38–1.25 48 1.00
First incidence 41 0.84 0.58–1.20 114 1.00
Haematological diseases
Prevalent at time of death 0 0.00 - 3 1.00
Incident one year prior to death 3 0.55 0.16–1.92 14 1.00
First incidence 11 0.72 0.37–1.41 43 1.00
Endocrine diseases
Prevalent at time of death 7 0.62 0.28–1.41 35 1.00
Incident one year prior to death 11 0.73 0.37–1.43 40 1.00
First incidence 64 0.73 0.55–0.96 238 1.00*
Mental diseases
Prevalent at time of death 1 0.20 0.03–1.52 12 1.00*
Incident one year prior to death 2 0.33 0.07–1.48 13 1.00
First incidence 23 0.92 0.56–1.49 63 1.00
Diseases of the nervous system
Prevalent at time of death 0 0.00 - 10 1.00
Incident one year prior to death 2 0.27 0.06–1.17 19 1.00*
First incidence 38 0.57 0.40–0.81 183 1.00*
Circulatory diseases
Prevalent at time of death 20 0.70 0.42–1.15 74 1.00
Incident one year prior to death 20 0.73 0.44–1.21 70 1.00
First incidence 122 0.90 0.73–1.11 360 1.00
Respiratory diseases
Prevalent at time of death 6 0.54 0.22–1.33 26 1.00
Incident one year prior to death 9 0.49 0.24–1.02 44 1.00*
First incidence 50 0.83 0.60–1.15 157 1.00
Diseases of the digestive system
Prevalent at time of death 7 0.72 0.31–1.68 23 1.00
Incident one year prior to death 9 0.85 0.39–1.81 27 1.00
First incidence 92 0.94 0.74–1.20 246 1.00
Diseases of the locomotion system
Prevalent at time of death 0 0.00 - 5 1.00
Incident one year prior to death 7 0.94 0.39–2.26 20 1.00
First incidence 152 1.12 0.92–1.36 347 1.00
Diseases of the kidney/urinary system
Prevalent at time of death 2 0.59 0.12–2.82 8 1.00
Incident one year prior to death 6 0.66 0.26–1.63 22 1.00
First incidence 59 0.86 0.64–1.15 181 1.00
Accidents/external causes
Prevalent at time of death 3 1.07 0.27–4.31 6 1.00
Incident one year prior to death 13 0.80 0.43–1.51 40 1.00
First incidence 213 1.06 0.90–1.25 512 1.00
TT TA and AA
Other/unspecified diseases{
Prevalent at time of death 5 0.68 0.25–1.86 17 1.00
Incident one year prior to death 19 0.56 0.34–0.92 83 1.00*
First incidence 143 0.96 0.79–1.16 380 1.00
Cox proportional hazards analysis with age as the underlying time scale and
delayed entrance at age at time of blood sampling (S-46). Cause of death
information was not available in 21 men who died after December 31, 2006.
*p,0.05 for the likelihood ratio test (Likelihood ratio tests were used to
estimate whether a model including both BMI S-20, BMI S-46 and FTO
rs9939609 fitted the data better than a model including only BMI S-20 and BMI
S-46)
{p,0.05 for interaction between genotype and the original sampling variable
(random vs. obese); the interaction term is included in the model
{The category other/unspecified diseases includes benign neoplasms, diseases
of the eye, skin and subcutaneous tissue, congenital malformation of the
urinary system and symptoms, signs and abnormal clinical and laboratory
findings, not otherwise classified.
doi:10.1371/journal.pone.0004428.t004
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groups. The accessibility of complete register-based data on
morbidity and mortality is an asset of the study, although the
clinical routine procedure generating the information requires
cautious interpretation. The sample size may seem small for a
genetic association study, but this apparent limitation is
counteracted by the fact that the random sample is represen-
tative of 175,000 men, among whom the obese participants
represents the most extreme rangeo ff a t n e s sp h e n o t y p e si nt h e
same population, except for the possible selective attrition
before S-46, where the genotyping was performed. The obese
group exhibited the expected excess mortality relative to the
randomly sampled group. The finding that circulatory diseases
and cancers were the categories with the largest number of
cases, further confirmed that the sample was representative of
the general male population, since these are listed as main
causes of death in the Danish male population [26]. Further, we
investigated morbidity and mortality in middle-aged men,
hence, we cannot conclude on the FTO SNP’s impact on
disease-risk in childhood or young adulthood. The major
limitation of the study is that the number of deaths is too small,
and the information about the diseases leading to death too
crude, to conduct a thorough disease-specific genotype-pheno-
type investigation. Given these limitations, analyses of the
reasons for the excess mortality obviously need to be explored in
other populations of both men and women.
In conclusion, the FTO SNP, rs9939609, may have a fatness-
independent impact on mortality and morbidity leading to death,
with a general lower risk in the TT genotype compared with A-
allele carriers.
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